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Mammalian SWI/SNF enzymes are ATP-dependent remodelers of chromatin structure. 
These multisubunit enzymes are heterogeneous in composition; there are two 
catalytic ATPase subunits, BRM and BRG1, that are mutually exclusive, and additional 
subunits are incorporated in a combinatorial manner. Recent findings indicate that 
approximately 20% of human cancers contain mutations in SWI/SNF enzyme subunits, 
leading to the conclusion that the enzyme subunits are critical tumor suppressors. 
However, overexpression of specific subunits without apparent mutation is emerging 
as an alternative mechanism by which cellular transformation may occur. Here we 
highlight recent evidence linking elevated expression of the BRG1 ATPase to tissue-
specific cancers and work suggesting that inhibiting BRG1 may be an effective 
therapeutic strategy.
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Mammalian SWI/SNF complexes are 
chromatin remodeling enzymes
In vitro biochemical approaches demon-
strated that mammalian SWI/SNF com-
plexes altered the structure of reconstituted 
chromatin particles in an ATP-dependent 
manner and made chromatin more acces-
sible for transcription factor binding [1–3]. 
SWI/SNF enzymes associate with chro-
matin via protein:protein and nonspecific 
protein:chromatin interactions [4]. Work on 
the enzymatic mechanism of ATP-dependent 
chromatin remodeling has been an ongoing 
endeavor and has been summarized else-
where [5–8]. Evidence that mammalian SWI/
SNF enzymes altered cellular chromatin was 
demonstrated by changes in nuclease acces-
sibility upon experimental manipulations to 
block the association of the enzyme with the 
transcriptional machinery or to express an 
enzymatically dead ATPase [9,10]. Over the 
last 15 or so years, biological roles for mam-
malian SWI/SNF enzymes and the individ-
ual subunits have been established in devel-
opment and tissue differentiation as well 
as in response to signaling mechanisms of 
many kinds [11–14]. Mammalian SWI/SNF-
mediated chromatin remodeling has effects 
on transcription, replication, repair and 
recombination, though research in the area 
of regulation of gene expression has been the 
most extensively pursued. While it is known 
that mammalian SWI/SNF enzymes regu-
late some constitutively expressed genes [15], 
enzyme activity is most closely linked to 
changes, or in some cases, reprogramming of 
gene expression in response to  developmental, 
environmental or other signaling cues.
One of the more remarkable properties 
of the mammalian SWI/SNF enzymes is 
the heterogeneity of enzyme composition. 
Several of the subunits derive from differ-
ent genes that encode similar but distinct 
proteins, splice variants for some subunits 
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exist and different subunits show preferential associa-
tion or mutual exclusivity with others [16]. Few of the 
subunits are found as independent proteins or as part 
of other protein complexes. Of particular relevance is 
the finding that there are two highly related but mutu-
ally exclusive ATPases, called BRM and BRG1, that 
act as the catalytic subunit for mammalian SWI/SNF 
enzymes [1–3,17,18]. The ATPases belong to the SNF2 
family of DNA-dependent ATPases that are related to 
DExx-box helicases, yet these proteins show no heli-
case activity [19,20]. In vitro, BRG1 and BRM have 
similar biochemical properties [21,22], but in cells they 
have both overlapping and differing roles [23–26]. The 
functional specificities, and even the biological needs 
for differently assembled enzyme complexes, remain 
an enigma.
The catalytic ATPase subunits, BRG1 and BRM, 
are multidomain proteins that contain both DNA and 
protein interaction modules (Figure 1). These homologs 
share 86% similarity at the protein level [27]. Among 
the conserved protein domains is the ATPase domain 
that defines the broader family of SNF2 ATPases, 
which translate the energy generated by ATP hydroly-
sis to mechanical motion on DNA templates [20]. Fine 
structure analysis of the ATPase domain by both muta-
tional structure-function analyses and crystallography 
has provided details about ATP binding and hydrolysis 
that reflect the common mechanism of action of this 
domain among the SNF2 ATPase family members [19]. 
The function of the BRK domain is unknown, but the 
presence of this domain is associated with helicases 
and transcription factors [28]. QLQ domain function 
is also unknown but has been postulated to mediate 
protein:protein interactions [29,30]. The HSA domain 
mediates intracomplex protein:protein interactions 
between BRG1 and the BAF250a/ARID1A subunit and 
is required for BRG1-dependent transcriptional activa-
tion by nuclear hormone receptors [31]. This domain is 
also required for interactions with the Ku70 protein, 
which links BRG1 with topoisomerase 2β and PARP1 
as part of the activation complex necessary for nuclear 
hormone-mediated gene activation [32]. Three domains 
contribute to chromatin binding. The Snf2 ATP cou-
pling (SnAC) domain is conserved among Snf2 ATPases 
but has been characterized only in the yeast Snf2/Swi2 
protein. SnAC and ATPase domains directly bind to the 
histone proteins when SWI/SNF enzymes are bound 
to nucleosomes, and the SnAC domain is essential for 
ATPase and chromatin remodeling activities [33,34]. The 
AT hook is a nonspecific DNA binding domain [35]. 
Bromodomains [36] are 110 amino acid domains that are 
found in many chromatin-associated proteins. Bromo-
domains can interact specifically with acetylated lysines 
present on histone H3 and H4 tails [37,38].
Mammalian SWI/SNF enzymes are linked to 
cancer
The first definitive link between mammalian SWI/
SNF enzymes and cancer came from a seminal study 
identifying the loss of the subunit called INI1/hSNF5/
BAF47 as causal for development of pediatric rhab-
doid tumors [39]. Early mouse studies indicated that 
Ini1 as well as the Brg1 ATPase subunit were tumor 
suppressor proteins [23,40–43]. These findings were 
consistent with cell culture-based and subsequent 
mouse modeling studies finding functional interac-
tions between BRG1 and numerous cell cycle regula-
tory proteins, including Rb, p53 and others [13,44,45]. 
Collectively, the data indicated that mammalian 
SWI/SNF enzymes normally contribute to cell cycle 
regulation and that loss of specific subunits and/or 
function result in cell cycle defects that could lead to 
tumor formation.
More recent studies using global approaches 
to identify mutations associated with cancer have 
revealed that human SWI/SNF enzyme subunits and 
proteins that associate with these subunits are mutated 
in approximately 20% of all human cancers [46,47], 
with suggestions that the actual frequency may be 
higher [48]. Loss or mutation of BRG1 has been doc-
umented in a number of cancers, including, but not 
limited to, lung, small cell carcinoma of the ovary, 
hypercalcemic type, medulloblastoma and Burkitt’s 
lymphoma. These findings have led to discussions of 
strategies to reverse the effects of mutations, especially 
mutations that result in silencing of the expression 
of one or more subunits, as a novel epigenetics-based 
approach to cancer therapy [48–50]. In addition, consid-
erable attention has been given to the idea of inducing 
synthetic lethality; targeting the BRM ATPase in can-
cers already containing nonfunctional BRG1 may be 
an effective strategy to treat such tumors [51–53]. Note, 
however, that some tumors, including lung and small 
cell carcinoma of the ovary, hypercalcemic type, lack 
both BRG1 and BRM [54–56], providing additional 
complexity to rational design approaches to restoring 
BRG1 or BRM function.
While the idea that mutation or loss of SWI/
SNF subunit proteins, because they are ubiquitously 
expressed and are essential contributors to gene expres-
sion, replication, repair and recombination, will lead 
to cellular transformation is well established, it is 
important to remember that mammalian SWI/SNF 
enzyme function is highly context-dependent. The 
enzymatic activity generates changes in chromatin 
accessibility, which can either negatively or positively 
affect chromatin utilization. Thus, it should not seem 
unexpected that overexpression of SWI/SNF subunits 
may similarly cause initiation or acceleration of cancer 
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Figure 1. Domain structure of BRG1. Conserved domains are labeled. Numbers across the top of the schematic 
represent amino acids.
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progression. In this review, we will concentrate on an 
emerging theme: overexpression of the BRG1 ATPase 
is correlated with tumorigenesis.
BRG1 is unlikely to be a tumor suppressor for 
breast cancer
The initial evidence suggesting that BRG1 was a 
tumor suppressor protein came from knockout mouse 
studies. A null mouse was embryonic lethal, while 
heterozygotes presented with mammary carcino-
mas [23,40]. At issue was the relatively low frequency 
(9%) of mammary tumor incidence, and subsequent 
work indicating that mammary-specific genetic deple-
tion of the gene encoding BRG1 did not result in 
mammary tumors [40,57]. Initial exome sequencing 
of 507 primary breast tumors failed to identify any 
tumors with mutant BRG1 [58], while later analysis of 
the TCGA database indicates less than 2% mutation 
frequency [48].
These potentially puzzling observations were sup-
ported by other work using human cell lines. Knock-
down of BRG1 in mammary epithelial cells slowed 
the rate of proliferation [59], instead of inducing more 
aggressive characteristics of a cell type that had lost a 
tumor suppressor. Knockdown of BRG1 in breast can-
cer cells similarly resulted in a reduction in the rate of 
proliferation in culture [60,61] and in orthotopic xeno-
grafts [61]. Complete knockout of BRG1 by CRISPR/
CAS9 technology resulted in cell death, affirming a 
requirement for BRG1 in breast cancer cell viabil-
ity [61]. Immunohistochemistry studies of primary 
breast tumors showed elevated BRG1 expression in 
35% to nearly 100% of samples [60–62], cementing the 
conclusion that elevated BRG1 expression correlates 
with breast tumorigenesis. Importantly, high BRG1 
expression was correlated with poor overall patient 
survival [60–62], raising the possibility that BRG1 
could be used as a prognostic indicator. In particu-
lar, Do et al. have argued that high BRG1 expression 
levels in invasive ductal carcinoma patients are a pre-
dictive marker for patients at high risk of developing 
metastases [62].
BRG1 likely promotes breast cancer cell 
proliferation through multiple mechanisms
Triple negative breast cancer is characterized by the 
absence of the estrogen receptor (ER), the progester-
one receptor (PR) and low to normal levels of HER2, 
a receptor tyrosine kinase encoded by the ERBB2 
gene that is often amplified or overexpressed in breast 
cancer. Absence of these markers means that the use 
of therapeutic approaches targeting these markers 
is not possible, and patients can only be treated by 
less specifically targeted cytotoxic drugs. Our recent 
work has demonstrated that BRG1 promotes triple 
negative breast cancer cell proliferation via multiple 
mechanisms. First, BRG1 promotes lipid, and specifi-
cally, fatty acid synthesis in support of cell prolifera-
tion [63]. Tumor cells typically use de novo fatty acid 
synthesis pathways even when exogenous fatty acids 
are available [64], and key enzymes in fatty acid and 
lipid synthesis are frequently overexpressed in breast 
cancer [65,66]. Knockdown of BRG1 in triple negative 
breast cancer cells substantially lowered de novo lipid 
synthesis, which correlated with decreased cell pro-
liferation. Subsequent investigation determined that 
BRG1 upregulates expression of enzymes responsible 
for fatty acid and lipid biosynthesis and likely does so 
in a direct manner, as BRG1 binds at the loci encod-
ing these genes [63]. The generality of these findings in 
other types of breast cancer awaits further study.
Our work also demonstrated that BRG1 upregulates 
ATP-binding cassette (ABC) transporter expression 
in response to drug treatment [67]. ABC transporters 
comprise a large family of highly conserved, ATP-
dependent, membrane-associated protein complexes 
that perform cellular import and export of numerous 
substrate molecules. Some ABC transporters are of 
great importance in cancer treatment because chemo-
therapeutic drugs can induce transporter expression, 
which can lead to increased export of and resistance 
to the drug [68]. Recent reports showed that BRG1 
knockdown increased chemosensitivity to an assort-
ment of chemotherapeutic drugs currently used in the 
clinic [67,69–72]. Some of these results were attributed 
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to BRG1-dependent induction of ABC transporter 
expression [67,71]. Knockdown of BRG1 abrogated 
transporter induction, and, importantly, increased the 
intracellular concentration of the drugs, which explains 
the observed chemosensitivity [67].
ER and/or PR positive breast cancers may be reg-
ulated by BRG1 by additional mechanisms. BRG1 
associates with ER and is required for ER-mediated 
transcriptional activation [73–75]. Similarly, progestin-
induced gene activation involves BRG1 and the SWI/
SNF enzyme complex [76,77]. It is possible that BRG1 
contributes to cancer progression driven by dysregu-
lated ER and/or PR signaling, but exact mechanisms 
remain to be determined.
BRG1 has a positive role in promoting 
proliferation in other cancer cell types
BRG1 is required for proliferation of HeLa cells via 
its regulation of p53 function [78]. Other works con-
cluded that acute myeloid leukemia cells require 
BRG1 for proliferation and survival [79,80]. BRG1-
dependent survival was linked to BRG1-dependent 
chromatin remodeling function at the MYC locus that 
resulted in hematopoietic transcription factors bind-
ing to enhancer sequences and the formation of a loop 
between the factor-bound enhancer and the promoter, 
which stimulated MYC gene expression [79]. Small 
cell lung cancer tumor cells that contain mutations 
in the Myc-associated factor MAX also require BRG1 
for proliferation and survival [81]. In contrast, BRG1 
knockdown in small cell lung cancer cells with wild-
type MAX showed no effect on proliferation or viabil-
ity, leading to the conclusion that BRG1 function is 
necessary for cell survival in the absence of functional 
MAX. These data, like those described for breast can-
cer, are not consistent with BRG1 functioning as a 
 classical tumor suppressor.
BRG1 is expressed at elevated levels in other 
tumor types
Melanoma
Melanocytes, pigment-producing cells, exist in a num-
ber of locations in the body but are best known for 
protecting the epidermis against the harmful effects 
of UV radiation. Melanocytic neoplasms originate 
from neural crest-derived melanocytes and can range 
from benign melanocytic naevi to malignant mela-
noma, which is considered to be the most aggressive 
form of skin cancer. The development and progression 
of melanoma have been attributed to independent or 
combined genetic and epigenetic events involving the 
RAS/RAF/MAPK, JNK, PI3K/Akt and Jak/STAT 
signaling pathways. Microphthalmia-associated tran-
scription factor (MITF), the lineage determinant that 
drives expression of melanocyte-specific genes, is also 
implicated in melanocyte transformation [82,83].
There appears to be some redundancy in the func-
tion of BRG1 and the related BRM ATPase in promot-
ing melanoma cell proliferation; knockdown of both, 
or of one if only one is present, blocks cell division [84–
86]. Investigation of BRG1 and BRM expression in pri-
mary tumors resulted in clear evidence of high levels 
of both in primary as well as in metastatic melano-
mas [84,87]. Mutation of BRG1 appears to be rare [88]. 
Patient survival data indicate a trend showing that low 
to moderate BRG1 expression improves short-term 
survival, but to date there is no statistical correlation 
between BRG1 expression and long-term patient sur-
vival [84]. Based on correlation between BRG1 expres-
sion and cell cycle regulators affected by BRG1, it has 
been proposed that the critical BRG1 function is in the 
initiation stages of melanoma progression [84], though 
it appears that BRG1, and possibly BRM, function 
contributes throughout melanoma progression [87].
The mechanism of SWI/SNF function in mela-
noma appears to be predominantly through regula-
tion of gene expression. MITF requires functional 
SWI/SNF ATPases to promote melanocyte differen-
tiation [89]. Similarly, the SWI/SNF ATPases promote 
MITF-driven transcription in melanoma cells and 
further add to the increased transcriptional activity of 
MITF target genes by stimulating increased expression 
of MITF itself [85,86]. Genes altered by manipulation of 
BRG1 and BRM expression include those affecting cell 
proliferation and survival, consistent with observed 
changes in cell cycle progression [84–86]. BRG1 and 
MITF physically interact and associate at melanocyte-
specific promoters [86,87,90] as well as at the MITF pro-
moter [85], suggesting direct contribution to target gene 
expression. Protection against UV-induced cell death 
specifically requires BRG1 to activate an inhibitor of 
apoptosis that is a transcriptional target of MITF [91]. 
SWI/SNF ATPases also promote the expression of 
prosurvival genes in melanoma cells that are not MITF 
dependent [92], indicating that BRG1 and the related 
BRM ATPase coactivate multiple transcriptional reg-
ulatory factors in melanoma. Of particular interest, 
BRG1 stimulates the expression of genes that encode 
proteins involved in melanoma invasiveness [87]. A 
recent study showed that BRG1 is recruited by MITF 
and SOX10 to a set of MITF-associated regulatory 
elements at active enhancers [93]. The distinct pattern 
of binding by MITF, SOX10 and two other transcrip-
tion factors between two BRG1-occupied nucleosomes 
determines a specific chromatin organization of the 
regulatory elements that is essential for gene expres-
sion and biological function. BRG1 also regulates the 
dynamics of MITF genomic occupancy. The interplay 
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between MITF and BRG1 thus plays an essential role 
in transcription regulation in melanoma.
Neuroblastoma/medulloblastoma/glioma
A limited number of studies examining BRG1 in dif-
ferent kinds of brain or nervous system tumors provide 
evidence of elevated levels of BRG1 in these tumors. In 
a recent study, BRG1 was found to be overexpressed 
in advanced neuroblastomas and associated with poor 
prognosis for neuroblastoma patients [94]. Reduction in 
BRG1 levels in neuroblastoma cell lines led to slow pro-
liferation in culture and in mouse xenografts. Global 
gene expression analysis showed that BRG1 depletion 
mainly affected genes associated with cell growth and 
proliferation, cell death and survival, including compo-
nents of the PI3K/AKT pathway [94]. In another study, 
knockout of Brg1 in a sonic hedgehog-type medul-
loblastoma mouse model markedly attenuated tumor 
formation and progression [95]. Global gene expression 
studies revealed that Brg1 functioned as a coregulator 
for key transcription factors, including Gli1, Atoh1 and 
REST, to control Shh-type medulloblastoma growth. 
Furthermore, these authors demonstrated that Brg1 
controls gene expression at least in part through epi-
genetic mechanisms involving the regulation of histone 
H3K27 methylating and demethylating enzymes [95]. 
Note, however, that there are multiple types of human 
medulloblastomas; two other types have been associ-
ated with heterozygous missense or in-frame Ins/Del 
mutations in BRG1 [47,95]. Such mutations likely result 
in loss of one or more BRG1 functions, though domi-
nant gain of function changes from these mutations 
remain a possible explanation for the observed pheno-
types. Therefore, it is possible that BRG1 functions as 
a tumor driver or a tumor suppressor in the context 
of different types of medulloblastomas. Both benign 
and malignant gliomas, tumors of the glial cells, have 
increased levels of BRG1 relative to nontumorigenic 
adjacent tissue [96]. Knockdown of BRG1 in glioma 
cells led to reduced cell proliferation via a reduction 
in cyclin D1 and a reduction in in vitro migration and 
invasion, which was linked to downregulation of the 
matrix metalloprotease MMP2 [96].
Colon/colorectal cancer
Colorectal cancer (CRC) results from an accumulation 
of genetic and epigenetic changes in colon epithelial 
cells, which transforms them into adenocarcinomas [97]. 
In primary colorectal tumors, BRG1 expression was 
frequently elevated, and knockdown of BRG1 reduced 
cell proliferation in primary tumor-derived cancer cells 
in culture [98]. Further analysis showed that BRG1 
inhibited expression of the PTEN tumor suppressor. 
PTEN normally suppresses PI3K-Akt signaling in all 
cells; BRG1 knockdown, therefore, elevated PTEN, 
further reduced active components of the PI3K-AKT 
signaling pathway, and reduced cyclin D1 levels, all of 
which contributed to the slow proliferation phenotype 
that was observed. BRG1 overexpression, reduced or 
absent PTEN expression and elevated cyclin D1 lev-
els were correlated in 35% of CRC primary tumors, 
suggesting misregulation of this  pathway in a sizable 
number of CRC patients [98].
In a clinical analysis of colon cancer, BRG1 expres-
sion levels were positively correlated with cancer pro-
gression and negatively correlated with patient sur-
vival. Reduction of BRG1 levels resulted in reduced cell 
proliferation in culture and reduced tumor growth in 
orthotopic transplants [99]. Prior studies had implicated 
WNT3A as a regulator of colon cancer cells [100]. Fur-
ther examination of primary tumors revealed a positive 
correlation between BRG1 and WNT3A expression. 
As would be predicted, BRG1 knockdown reduced 
WNT3A expression in cultured cells, and reintroduc-
tion of WNT3A rescued the cell  proliferation defect 
caused by BRG1 knockdown [99].
Studies of BRG1 in CRC metastasis illustrate the 
complex functions of BRG1. In contrast to the work 
just described, loss of BRG1 promotes CRC metasta-
sis in culture and in animal models. BRG1 expression 
inversely correlated with metastasis, and knockdown 
enhanced metastatic cancer cell mobility, migration 
and invasiveness through an axis of regulators involv-
ing miRNA regulation of a regulator of Wnt/β-catenin 
signaling [101]. Follow-up studies concluded that BRG1 
reduction or loss promoted lymphangiogenesis in 
colorectal tumors through regulation of STAT3 acti-
vation and VEGF expression [101]. Collectively, these 
studies provide an intriguing contrast in the conse-
quences of misregulation of BRG1. Additional studies 
will be needed to better define the oncogenic versus 
tumor suppressive properties of BRG1 in CRC.
Pancreatic cancer
Pancreatic ductal adenocarcinoma (PDA), the most 
common form of pancreatic cancer, can arise from 
precursor lesions via distinct mechanisms. Included 
among these, precancerous lesions are pancreatic 
intraepithelial neoplasia, which derives from exocrine 
acinar cells [102], and intraductal papillary mucinous 
neoplasia (IPMN), which derives from pancreatic 
ductal epithelial cells [103]. Numerous reports indicate 
a tumor suppressive role for BRG1 in PDA. Examin-
ing BRG1 levels in IPMN lesions revealed that lower 
Brg1 expression was more frequently observed in high-
grade IPMNs compared with intermediate-grade and 
low-grade IPMNs [104]. Additional studies identified 
PDA tumors containing mutations in BRG1 and other 
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SWI/SNF subunits, albeit at low frequency [105–107]. 
These results seem to indicate that BRG1 has a tumor 
suppressor role in pancreatic cancer.
However, other work indicates that the role of BRG1 
in pancreatic cancer is not necessarily clear. A study of 
primary tumor samples showed that expression of both 
BRG1 and the related BRM ATPase were correlated 
with disease state, and that high levels of BRM was 
prognostic for poor survival [108]. Another study also 
found high levels of BRG1 expression in primary tumor 
samples and that BRG1 knockdown in pancreatic can-
cer cell lines reduced cell proliferation in culture and 
in xenografts and decreased AKT signaling [72]. BRG1 
knockdown also reduced chemoresistance to a specific 
chemotherapeutic drug. Though the mechanism was 
not defined, the result is consistent with our previously 
described studies showing that BRG1 is required for 
drug-induced ABC transporter induction [67].
Most pancreatic adenocarcinomas contain muta-
tions in the KRAS gene that encodes a GTPase that 
is integral to many cellular signaling pathways [109]. 
Mouse modeling determined that depletion of Brg1 
cooperated with mutant Kras to rapidly form IPMN-
like lesions that then progressed to PDA. In contrast, 
loss of Brg1 inhibited mutant Kras-driven formation of 
PanID lesions from adult acinar cells [103]. These data 
indicate that BRG1 has opposing roles in the devel-
opment of different precancerous lesions that lead to 
PDA. Subsequent studies showed even greater com-
plexity to Brg1 function, as the same research team 
examined IPMN progression to PDA in detail. They 
determined that the ductal cells from which IPMN is 
derived undergo dedifferentiation as part of the tumor-
igenic process; Brg1 functions as a tumor suppressor at 
this stage to prevent dedifferentiation and tumor ini-
tiation. However, once PDA forms, Brg1 drives PDA 
progression by inducing an epithelial to mesenchymal 
transition. Therefore, Brg1 prevents and promotes 
pancreatic cancer in a stage-specific manner [110]. Rec-
onciling these conflicting roles for Brg1 and exploit-
ing this information therapeutically for PDA awaits 
 further work.
Other cancers
Additional tumor types where elevated BRG1 expres-
sion has been reported include gastric, prostate and 
intestinal cancers. Approximately 60% of the gastric 
carcinomas assayed showed elevated levels of BRG1 
relative to non-neoplastic mucosa, and tumors at 
more advanced stages showed further increased levels 
of BRG1. Assessment of genetic alterations in BRG1 
present in the tumors or in eight gastric carcinoma 
cell lines failed to identify any mutations, suggesting 
that elevated expression was associated with the devel-
opment and progression of the tumor [111]. However, 
a different report indicated that BRG1 or one of the 
other SWI/SNF enzyme subunits was mutated in 
approximately 30% of gastric cancers [112], similar to 
what was reported by another group studying pan-
creatic cancer [106]. The reason for the discrepancy 
remains to be addressed. Elevated levels of BRG1 have 
been reported in prostate cancer, with BRG1 expression 
level correlating with advancement of the tumor [113]. 
In one of the few reported instances of successful over-
expression of BRG1, these authors showed that over-
expression of wildtype but not a catalytically inactive 
BRG1 increased prostate cancer cell line invasiveness 
in vitro [113]. Finally, mouse modeling of intestinal 
cancer demonstrated that knockout of Brg1 in small 
intestine epithelium or in the intestinal stem cell popu-
lation attenuated expression of Wnt target genes and 
suppressed Wnt-driven tumor initiation [114], providing 
evidence for a tumor promoting function for Brg1.
The impact of BRG1 in cancer
Collectively, these findings reveal the influences of 
BRG1 on a number of signaling pathways and processes 
that ultimately impact cell proliferation and survival 
(Figure 2). The summary diagram is no doubt oversim-
plified; there are likely many additional pathways that 
are impacted by BRG1 and that converge downstream 
on cell proliferation and survival. Nevertheless, the 
findings to date have provided evidence that multiple 
tumor types show elevated levels of BRG1 and that 
targeting BRG1 suppresses cell proliferation. Thus, for 
certain types of cancer, BRG1 function represents a 
target to exploit for therapeutic purposes.
Strategically targeting BRG1 for cancer therapy
In theory, elevated expression of any protein without 
mutation in a tumor cell makes that protein a potential 
target for therapeutic purposes. However, proteins that 
are ubiquitously expressed, such as BRG1, may seem 
to be of questionable value as targets. Nevertheless, 
emerging data support the idea that targeting BRG1 
is a viable option. Rationales fall into two categories: 
targeting BRG1 as a regulator of cancer-driving path-
ways and inhibiting BRG1 as a method to increase the 
chemosensitivity of drugs already in use in the clinic.
We have discussed roles of BRG1 in specific path-
ways critically involved in cellular transformation. 
BRG1 plays a critical role in driving cancer-specific 
metabolic pathways in breast cancer and is linked to 
different signaling pathways that promote colorectal 
and pancreatic cancer, neuroblastoma, medulloblas-
toma and melanoma. Reducing BRG1 expression in 
tumor cells, and in some cases, orthotopic xenografts, 
consistently showed a reduction in cancer cell prolifera-
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Figure 2. Pathways implicated in BRG1 function in 
tumors and cancer cell lines showing elevated levels of 
BRG1. See text for details.
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tion. Thus, a mechanism to deliver knockdown vectors 
or identification of a small molecule inhibitor of BRG1 
should permit targeting of these BRG1 functions with 
a resulting reduction of cancer cell proliferation.
Recent reports show that reduction of BRG1 expres-
sion results in increased chemosensitivity to individual 
drugs that target rapidly dividing cancer cells [67,69–
72,115–117]. One study demonstrated that half a dozen 
chemotherapeutic drugs currently used in the clinic 
were more effective in killing breast cancer cells in 
which BRG1 expression was reduced, demonstrating 
the generality of this targeting strategy [67]. Impor-
tantly, the mechanism for increased tumor cell kill-
ing was a dependence on BRG1 for the drug-induced 
activation of ABC transporter gene expression [67]. 
Since ABC transporters often control the import 
and export of chemotherapy drugs, targeting BRG1 
should prevent or reduce ABC transporter induction 
and prevent transporter-mediated export of the drugs 
and treatment failure. Targeting BRG1, then, should 
be an effective adjuvant therapy for existing cancer 
treatments. Other studies linked the chemosensitiv-
ity observed upon BRG1 knockdown to deficiencies 
in DNA repair following exposure to DNA damaging 
chemotherapeutic drugs [115–117], suggesting another 
drug resistance mechanism that would be targeted by 
methods reducing BRG1 expression or function.
While methods for targeting cancer-driving pro-
teins by siRNA and for genome editing to alleviate the 
effects of mutation or misexpression progress, the clas-
sic approach of identifying inhibitors of target mole-
cules continues. Small molecule targeting of BRG1 
and related proteins has already begun.
PFI-3 is a small molecule inhibitor developed by 
Pfizer and the Structural Genomic Consortium that 
specifically targets the bromodomain of family VIII 
bromodomain proteins, which include BRG1, BRM and 
the Polybromo 1 (also called BAF180) subunit of SWI/
SNF enzymes. Embryonic stem cells treated with PFI-3 
showed reduced stemness potential and deregulated 
lineage specification, with markedly enhanced tropho-
blast differentiation [118]. Subsequent work determined 
that PFI-3 impaired both myoblast and preadipocyte 
differentiation [119]. However, PFI-3 had no effect on 
cell proliferation in various human cancer cell lines, 
perhaps because it failed to dislodge BRG1/BRM from 
chromatin [67,120]. It can, therefore, be concluded that 
the bromodomains of BRG1, BRM and Polybromo 1 
contribute to the balance between stemness and differ-
entiation, but are not required for BRG1- or SWI/SNF 
 enzyme-dependent cancer cell proliferation.
Active DNA-dependent ATPase A Domain inhibi-
tor (ADAADi) is a minor byproduct of the reac-
tion catalyzed by the bacterial aminoglycoside-3′-
phosphotransferase APH (3′)-III enzyme that can be 
separated by chromatographic steps [121,122]. ADAADi 
is an inhibitor of the ATPase activity of the SWI2/
SNF2 family of ATPases, and it specifically blocks 
nucleosome remodeling by BRG1-based SWI/SNF 
enzymes [121]. The activities of other related DNA-
dependent ATPases, RNA-dependent ATPases and 
DNA-independent ATPases are not affected by 
ADAADi [121]. In breast cancer cells, ADAADi prefer-
entially targets BRG1 over BRM, suggesting that some 
specificity may exist in vivo. Remarkably, treatment 
of breast cancer cells with ADAADi reduced cell pro-
liferation. Furthermore, ADAADi decreased de novo 
lipid synthesis in breast cancer but not breast epithelial 
cells and enhanced chemotherapy drug efficacy to the 
same extent as BRG1 knockdown [63,67]. Thus, each of 
the documented BRG1-dependent attributes of breast 
cancer cells could be abrogated by the inhibitor. This 
work provides the first proof of principle that a BRG1 
inhibitor can directly inhibit cancer cell proliferation 
as well as complement the chemotherapeutic activities 
of clinically relevant drugs currently used for patient 
treatment. Efforts to identify the active molecule in 
ADAADi and the discovery of additional BRG1 inhib-
itors will provide the oncology community with novel 
tools to augment current therapeutic approaches.
Future perspective
The BRG1 ATPase that drives some of the SWI/SNF 
chromatin remodeling enzymes is an intriguing con-
tributor to cancer. Its basic biochemical function, to 
disrupt histone:DNA contacts to alter nucleosome 
structure and/or positioning, makes its biological rel-
evance subject to its immediate cellular context. The 
chromatin remodeling activity can be used to promote 
the function of transcriptional activators as well as 
repressors and to facilitate replication, recombination 
and repair. Perhaps it is not so surprising, then, that in 
the context of cancer initiation and progression, BRG1 
activity can cooperate with factors promoting tumor 
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suppression as well as oncogenic factors promoting 
unregulated cell proliferation.
Surprising or not, this reality introduces significant 
complexity into understanding BRG1 function and 
mechanisms of action. Work on BRG1 and other SWI/
SNF enzyme subunits as tumor suppressors based on 
their mutation or loss of expression in some cancers 
continues, but there is now ample evidence that elevated 
BRG1 expression is associated with other cancer types 
and, at least in some cases, with poor prognosis. Con-
sequently, there are studies showing that reintroduc-
tion of BRG1 into tumor cells lacking BRG1 inhibits 
tumor cell proliferation as well as studies showing that 
proliferation of other tumor cell types can be inhibited 
by BRG1 knockdown or depletion. The recent studies 
of pancreatic cancer that showed both tumor suppres-
sive and tumor-promoting activities at different tumor 
stages demonstrates that BRG1 can have opposing 
functions even within the same cancer [103,110]. This 
reinforces the concept that BRG1 function is highly 
context dependent.
Many of the studies showing that alteration of 
BRG1 expression impact tumor cell proliferation 
include hypotheses stating that modulating BRG1 
expression may be a future therapeutic approach, but 
the conundrum is clear. Any therapeutic strategy is 
going to be particularly dependent on precise deliv-
ery of the BRG1 ‘modulator’ to the tumor. A further 
complication is the possible, or perhaps likely, effect 
of any therapeutic strategy targeting BRG1 on the 
other SWI/SNF enzyme subunits. Limited data exist 
on the relationship between BRG1 and BRM expres-
sion, though it has been documented that knockdown 
of one ATPase can lead to increased expression of the 
other [25,59,61]. The concept of functional compensation 
of one ATPase for the other provides additional hurdles 
in developing treatments based on either enzyme. In 
addition, there is still much to be learned about how 
manipulating one subunit will impact the expression 
of the other subunits, assembly of the enzyme complex 
and functional consequences on individual subunits 
and the enzyme itself.
Nevertheless, the community finds itself at the 
onset of an exciting new phase of research. The idea 
that a biologic or chemical inhibitor of BRG1 could 
be used to improve cancer therapy is tantalizing. To 
date, it is apparent that one bromodomain inhibitor, 
though clearly modulating SWI/SNF function in 
developmental processes, had no impact on the pro-
liferation of any of a number of different tumor cell 
types [67,118–120]. Whether other bromodomain inhibi-
tors are similarly ineffective remains to be determined, 
it has been reported that ectopic expression of the 
BRG1 bromodomain increased the radiosensitivity of 
cancer cells [123]. An inhibitor of the BRG1 ATPase 
domain, however, showed dramatic effects in inhibit-
ing cancer cell proliferation and in inhibiting BRG1-
specific underlying mechanisms driving increased 
lipid synthesis [63], giving credence to the idea that the 
ATPase domain, despite its conservation, is a viable tar-
get. The additional finding that the ATPase inhibitor 
increased chemosensitivity of known chemotherapeu-
tic drugs [67], combined with similar results based on 
BRG1 knockdown [67,69–72], raises the possibility that 
targeting BRG1 could complement existing cytotoxic 
drug use. The possibility of targeting other functional 
domains in BRG1 (Figure 1) is unknown. Undoubtedly 
the community will continue searching for additional 
molecules that can inhibit cancer cell proliferation, 
which we expect will be successful. The real challenge, 
and of course, interest, will be in the subsequent efforts 
to determine whether these molecules can be utilized 
beyond cultured cancer cell models to effectively and 
specifically target BRG1 in patient tumors.
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Executive summary
•	 BRG1, a catalytic subunit of the SWI/SNF family of ATP-dependent chromatin remodeling enzymes, has tumor 
suppressor activities, but is highly expressed in some tumor types without mutation.
•	 Characterization of BRG1 function in tumors with elevated BRG1 levels shows effects on signaling pathways 
that result in increased cancer cell proliferation and survival.
•	 Knockdown of BRG1 in tumor cell types that show elevated BRG1 levels suppresses proliferation and other 
cancer cell properties.
•	 An inhibitor of the ATPase activity of BRG1 similarly suppresses cancer cell proliferation and other cancer cell 
phenotypes and provides proof of principle that targeting BRG1 could be of therapeutic value.
•	 BRG1 knockdown or the BRG1 inhibitor increases chemosensitivity to cytotoxic drugs used clinically for 
cancer treatment, suggesting that BRG1 targeting could be a successful adjuvant therapy to existing 
chemotherapeutic approaches.
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